FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107935855> ?p ?o ?g. }

• W2107935855 endingPage "16" @default.
• W2107935855 startingPage "16" @default.
• W2107935855 abstract "For rare serious and life-threatening disorders, there is a tremendous challenge of transforming scientific discoveries into new drug treatments. This challenge has been recognized by all stakeholders who endorse the need for flexibility in the regulatory review process for novel therapeutics to treat rare diseases. In the United States, the best expression of this flexibility was the creation of the Accelerated Approval (AA) pathway. The AA pathway is critically important for the development of treatments for diseases with high unmet medical need and has been used extensively for drugs used to treat cancer and infectious diseases like HIV. In 2012, the AA provisions were amended to enhance the application of the AA pathway to expedite the development of drugs for rare disorders under the Food and Drug Administration Safety and Innovation Act (FDASIA). FDASIA, among many provisions, requires the development of a more relevant FDA guidance on the types of evidence that may be acceptable in support of using a novel surrogate endpoint. The application of AA to rare diseases requires more predictability to drive greater access to appropriate use of AA for more rare disease treatments that might not be developed otherwise. This white paper proposes a scientific framework for assessing biomarker endpoints to enhance the development of novel therapeutics for rare and devastating diseases currently without adequate treatment and is based on the opinions of experts in drug development and rare disease patient groups. Specific recommendations include: 1) Establishing regulatory rationale for increased AA access in rare disease programs; 2) Implementing a Biomarker Qualification Request Process to provide the opportunity for an early determination of biomarker acceptance; and 3) A proposed scientific framework for qualifying biomarkers as primary endpoints. The paper’s final section highlights case studies of successful examples that have incorporated biomarker endpoints into FDA approvals for rare disease therapies. The focus of this paper is on the situation in the Unites States, but the recommendations are reasonably applicable to any jurisdiction." @default.
• W2107935855 created "2016-06-24" @default.
• W2107935855 creator A5003149248 @default.
• W2107935855 creator A5006551650 @default.
• W2107935855 creator A5019320958 @default.
• W2107935855 creator A5027174356 @default.
• W2107935855 creator A5037586831 @default.
• W2107935855 creator A5040820898 @default.
• W2107935855 creator A5063276228 @default.
• W2107935855 creator A5070032933 @default.
• W2107935855 creator A5073047711 @default.
• W2107935855 creator A5076838888 @default.
• W2107935855 creator A5087103072 @default.
• W2107935855 date "2015-01-01" @default.
• W2107935855 modified "2023-09-27" @default.
• W2107935855 title "Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints" @default.
• W2107935855 cites W2009603917 @default.
• W2107935855 cites W2080675410 @default.
• W2107935855 cites W2120240121 @default.
• W2107935855 cites W2120368275 @default.
• W2107935855 cites W2160448958 @default.
• W2107935855 doi "https://doi.org/10.1186/s13023-014-0195-4" @default.
• W2107935855 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4347559" @default.
• W2107935855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25757705" @default.
• W2107935855 hasPublicationYear "2015" @default.
• W2107935855 type Work @default.
• W2107935855 sameAs 2107935855 @default.
• W2107935855 citedByCount "39" @default.
• W2107935855 countsByYear W21079358552015 @default.
• W2107935855 countsByYear W21079358552016 @default.
• W2107935855 countsByYear W21079358552017 @default.
• W2107935855 countsByYear W21079358552018 @default.
• W2107935855 countsByYear W21079358552019 @default.
• W2107935855 countsByYear W21079358552020 @default.
• W2107935855 countsByYear W21079358552021 @default.
• W2107935855 countsByYear W21079358552022 @default.
• W2107935855 countsByYear W21079358552023 @default.
• W2107935855 crossrefType "journal-article" @default.
• W2107935855 hasAuthorship W2107935855A5003149248 @default.
• W2107935855 hasAuthorship W2107935855A5006551650 @default.
• W2107935855 hasAuthorship W2107935855A5019320958 @default.
• W2107935855 hasAuthorship W2107935855A5027174356 @default.
• W2107935855 hasAuthorship W2107935855A5037586831 @default.
• W2107935855 hasAuthorship W2107935855A5040820898 @default.
• W2107935855 hasAuthorship W2107935855A5063276228 @default.
• W2107935855 hasAuthorship W2107935855A5070032933 @default.
• W2107935855 hasAuthorship W2107935855A5073047711 @default.
• W2107935855 hasAuthorship W2107935855A5076838888 @default.
• W2107935855 hasAuthorship W2107935855A5087103072 @default.
• W2107935855 hasBestOaLocation W21079358551 @default.
• W2107935855 hasConcept C105795698 @default.
• W2107935855 hasConcept C126322002 @default.
• W2107935855 hasConcept C142724271 @default.
• W2107935855 hasConcept C177713679 @default.
• W2107935855 hasConcept C203092338 @default.
• W2107935855 hasConcept C2778917124 @default.
• W2107935855 hasConcept C2779134260 @default.
• W2107935855 hasConcept C2779701055 @default.
• W2107935855 hasConcept C2780035454 @default.
• W2107935855 hasConcept C2780598303 @default.
• W2107935855 hasConcept C2781197716 @default.
• W2107935855 hasConcept C33923547 @default.
• W2107935855 hasConcept C535046627 @default.
• W2107935855 hasConcept C55493867 @default.
• W2107935855 hasConcept C60644358 @default.
• W2107935855 hasConcept C64903051 @default.
• W2107935855 hasConcept C71924100 @default.
• W2107935855 hasConcept C75480439 @default.
• W2107935855 hasConcept C86803240 @default.
• W2107935855 hasConcept C98274493 @default.
• W2107935855 hasConceptScore W2107935855C105795698 @default.
• W2107935855 hasConceptScore W2107935855C126322002 @default.
• W2107935855 hasConceptScore W2107935855C142724271 @default.
• W2107935855 hasConceptScore W2107935855C177713679 @default.
• W2107935855 hasConceptScore W2107935855C203092338 @default.
• W2107935855 hasConceptScore W2107935855C2778917124 @default.
• W2107935855 hasConceptScore W2107935855C2779134260 @default.
• W2107935855 hasConceptScore W2107935855C2779701055 @default.
• W2107935855 hasConceptScore W2107935855C2780035454 @default.
• W2107935855 hasConceptScore W2107935855C2780598303 @default.
• W2107935855 hasConceptScore W2107935855C2781197716 @default.
• W2107935855 hasConceptScore W2107935855C33923547 @default.
• W2107935855 hasConceptScore W2107935855C535046627 @default.
• W2107935855 hasConceptScore W2107935855C55493867 @default.
• W2107935855 hasConceptScore W2107935855C60644358 @default.
• W2107935855 hasConceptScore W2107935855C64903051 @default.
• W2107935855 hasConceptScore W2107935855C71924100 @default.
• W2107935855 hasConceptScore W2107935855C75480439 @default.
• W2107935855 hasConceptScore W2107935855C86803240 @default.
• W2107935855 hasConceptScore W2107935855C98274493 @default.
• W2107935855 hasIssue "1" @default.
• W2107935855 hasLocation W21079358551 @default.
• W2107935855 hasLocation W21079358552 @default.
• W2107935855 hasLocation W21079358553 @default.
• W2107935855 hasLocation W21079358554 @default.
• W2107935855 hasOpenAccess W2107935855 @default.
• W2107935855 hasPrimaryLocation W21079358551 @default.
• W2107935855 hasRelatedWork W1996639523 @default.

• next